Radar · Neurology in Massachusetts
Best Neurology Companies in Massachusetts, United States
The 212 best Neurology companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Neumora.
By Riya SenguptaFinancials
212companies tracked
$9.3Bdisclosed funding
1unicorns
144have raised
FLIAR INTELLIGENCE · NEUROLOGY × MASSACHUSETTS
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
5.2Mcombined LinkedIn audience
97%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Neurology companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Neumora Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders | $612M | 44 mo ago | 124 124 → 108 (-13%) · sector median +26% | Robert Nelsen Co-Founder | DrupalApple iCloud MailMicrosoft 365+30 | — | — |
| 2 | Seaport Therapeutics Developer of therapeutics to treat neuropsychiatric disorders | $325M | 20 mo ago | — | Steven Paul Co-Founder | WordPressApple iCloud MailMicrosoft 365+18 | — | 1 award |
| 3 | Lyndra Developer of oral drug delivery formulations | $305M | 30 mo ago | 107 | Andrew Bellinger Co-Founder | — | 51 patents Patents concentrated in health & consumer products | — |
| 4 | Rapport Provider of neuro medicines development and communication services | $250M | 33 mo ago | 25 | David Bredt Founder | WordPressApple iCloud MailMySQL+27 | — | — |
| 5 | Minerva Neurosciences Innovating central nervous system disorder treatments with clinical expertise and patient focus 50Patents top 22%Funding top 26%Innovation top 27%Fin. health bottom 48% All 9 signals ▾Patentstop 22% Fundingtop 26% Innovationtop 27% Fin. healthbottom 48% Moatbottom 48% Globalbottom 44% Techbottom 40% Marketbottom 38% Newsbottom 38% Patents: 216 patents matched (strict assignee match) · 111 filings since 2022 vs 89 in 2017-21 Funding: Raised $247M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $247M | 7 mo ago | 10 | — | WordPressMySQLPHP+14 | 216 patents Novel CNS drug molecules and gastro-resistant oral formulations for psychiatric and metabolic disorders | — |
| 6 | Alzheon Developer of disease-modifying treatments for Alzheimer's disease and other neurodegenerative disorders | $228M | 24 mo ago | 22 | Martin Tolar Md Founder | WordPressMySQLPHP+26 | 184 patents Small-molecule sulfopropanoic acid derivatives for treating Alzheimer's and neurodegeneration | — |
| 7 | Cognito Therapeutics Developer of a medical device for the treatment of Alzheimer's disease 60Talent top 22%Funding top 23%Growth top 35%Moat top 42% All 8 signals ▾Talenttop 22% Fundingtop 23% Growthtop 35% Moattop 42% Techtop 50% Marketbottom 43% Globalbottom 37% Newsbottom 21% Talent: Analyst team rating 5/5 · 3 named leaders on record Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $227M | 3 mo ago | 42 | Ed Boyden Co-Founder | WebflowGSAPUnpkg+12 | — | — |
| 8 | CervoMed Developer of therapeutics for neurodegenerative diseases | $209M | 15 mo ago | 13 13 → 20 (+54%) · sector median +26% | John Alam Co-Founder & CEO | DrupalPHPBootstrap+21 | — | — |
| 9 | Apnimed Developer of small molecule based therapeutics for the treatment of obstructive sleep apnea 37Funding top 14%Growth top 28%Talent top 28%Moat top 35% All 12 signals ▾Fundingtop 14% Growthtop 28% Talenttop 28% Moattop 35% Producttop 40% Techbottom 49% Globalbottom 37% Patentsbottom 34% Marketbottom 32% Innovationbottom 21% Newsbottom 18% Customersbottom 3% Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $208M | 2 mo ago | 13 | Andrew Wellman Co-Founder | WordPressApple iCloud MailMySQL+21 | 2 patents Pharmaceutical solid‑form optimization and repurposed drug therapy for sleep‑apnea treatment | 1 job opening · 1 award |
| 10 | Cerevance Discovering and developing novel therapeutics for neurological and psychiatric disorders | $204M | 25 mo ago | 6 | — | — | 29 patents Design of heterocyclic small‑molecule inhibitors for CD38, GPR55 and KCNK13 targets | — |
| 11 | QurAlis Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS) 64Funding top 20%Patents top 23%Innovation top 25%Growth top 26% All 10 signals ▾Fundingtop 20% Patentstop 23% Innovationtop 25% Growthtop 26% Moattop 32% Talenttop 41% Techbottom 43% Globalbottom 42% Marketbottom 36% Newsbottom 22% Funding: Raised $144M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Patents: 69 patents matched (strict assignee match) · 62 filings since 2022 vs 7 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 9 mo ago | 38 38 → 87 (+129%) · sector median +26% | Kasper Roet Founder & CEO | WordPressApple iCloud MailMicrosoft 365+17 | 69 patents Antisense oligonucleotide therapeutics targeting UNC13A for neurological disease treatment | — |
| 12 | Vigil Developer of therapeutic solutions for treating multiple neurodegenerative diseases | $140M | 23 mo ago | 56 | Ivana Liebisch CEO & President | — | — | — |
| 13 | Cellino Developer of autologous cell therapies | $125M | 21 mo ago | 43 43 → 107 (+149%) · sector median +26% | Matthias Wagner Co-Founder & CTO | SanityNode.jsThree.js+11 | — | 1 award |
| 14 | Axial Therapeutics Developer of small molecule therapeutics for central nervous system disorder | $110M | 16 mo ago | 12 12 → 12 (+0%) · sector median +26% | A Campbell CEO | — | — | — |
| 15 | Atalanta Therapeutics Developer of RNAi therapeutics to treat neurodegenerative diseases | $110M | 16 mo ago | 62 | Neal Aronin Co-Founder | WordPressApple iCloud MailMicrosoft 365+29 | — | — |
| 16 | Totus Medicines Provider of genome-scale drug discovery platform to treat multiple diseases | $108M | 30 mo ago | 23 23 → 35 (+52%) · sector median +26% | Neil Dhawan Founder & CEO | — | 59 patents Patents concentrated in health & consumer products | — |
| 17 | PureTech Health Developer of immunotherapeutics for multiple diseases | $107M | 34 mo ago | 171 | Robert Langer Co-Founder | DrupalApple iCloud MailMicrosoft 365+27 | — | — |
| 18 | Voyager Therapeutics Neurogenetic medicine innovator, developing transformative treatments for neurological diseases | $105M | 29 mo ago | 183 183 → 161 (-12%) · sector median +26% | Steven Paul Co-Founder | WordPressApple iCloud MailMySQL+21 | 790 patents Engineered AAV gene therapy vectors for neurodegenerative and metabolic disorder treatment | — |
| 19 | Newleos Developer of oral small molecules for neuropsychiatric conditions treatment | $94M | 16 mo ago | — | Federico Bolognani Chief Medical Officer and co-Founder | — | — | — |
| 20 | Solid Biosciences Developer of gene therapy platform for Duchenne muscular dystrophy 53Patents top 20%Funding top 24%Innovation top 31%Tech top 33% All 10 signals ▾Patentstop 20% Fundingtop 24% Innovationtop 31% Techtop 33% Moattop 38% Newstop 48% Marketbottom 49% Growthbottom 44% Globalbottom 42% Fin. healthbottom 32% Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $92M | 3 mo ago | 101 | — | WordPressApple iCloud MailMySQL+22 | 60 patents AAV vector manufacturing and formulation for cardiac gene therapies | — |
| 21 | Rgenta Developer of RNA-based therapeutics for multiple disorders 32Talent top 28%Funding top 29%Moat top 39%Global bottom 39% All 6 signals ▾Talenttop 28% Fundingtop 29% Moattop 39% Globalbottom 39% Marketbottom 28% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $90.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $90M | 12 mo ago | 11 | Zhiping Weng Co-Founder | — | — | — |
| 22 | Biogen Developer of therapies for neurodegenerative and immunology disorders | $80M | 28 mo ago | 9,482 | Heinz Co-Founder | DrupalAdobe Experience ManagerApple iCloud Mail+25 | 3,803 patents Therapeutic biologics, antibodies, and gene‑therapy vectors for neuro‑immune diseases | — |
| 23 | Progentos Developer of regenerative medicines for multiple sclerosis and other degenerative diseases | $69M | 25 mo ago | — | Sanjay Magavi Co-Founder | — | — | — |
| 24 | Centrexion Developer of drugs for chronic pain management | $66M | 12 mo ago | 14 | Sol Barer Founder & Chairman | — | — | — |
| 25 | Alcyone Developer of gene therapies to treat neurological conditions | $56M | 15 mo ago | 32 | PJ Anand Founder | WordPressMySQLPHP+12 | — | — |
| 26 | Myrtelle Developer of gene therapies for the treatment of neurological diseases 35Funding top 31%Growth top 35%Moat top 45%Patents top 49% All 9 signals ▾Fundingtop 31% Growthtop 35% Moattop 45% Patentstop 49% Talentbottom 49% Innovationbottom 47% Techbottom 41% Globalbottom 37% Marketbottom 22% Funding: Raised $44.1M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $44M | 6 mo ago | 12 12 → 11 (-8%) · sector median +26% | Mark Pykett CEO | WordPressMySQLPHP+20 | 4 patents Therapeutic biotech targeting myelin repair and neurodegenerative disease treatment | — |
| 27 | PAQ Developer of small molecule therapeutics for neurodegenerative disease 24Funding top 27%Talent top 28%Moat top 39%News top 46% All 8 signals ▾Fundingtop 27% Talenttop 28% Moattop 39% Newstop 46% Patentsbottom 41% Globalbottom 37% Innovationbottom 33% Marketbottom 24% Funding: Raised $34.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 24/100 | $34M | 4 mo ago | 6 | Huaixiang Hao Co-Founder | — | 10 patents Airtight, child‑resistant, compartmentalized packaging for tobacco products | — |
| 28 | Sensorium Therapeutics Developer of therapeutics for psychiatric and neurological disorders | $30M | 13 mo ago | 23 | Alex Simon Co-Founder | WebflowTypekitGoogle Font API+12 | — | — |
| 29 | Quiver Bioscience Developer of transformational medicines for neurological disorders 67Talent top 28%Funding top 31%AI top 35%Market top 50% All 5 signals ▾Talenttop 28% Fundingtop 31% AItop 35% Markettop 50% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $28.9M across 16 rounds · 16 rounds over 8 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $29M | 2 mo ago | 48 | Paul Roma Co-Founder | — | — | — |
| 30 | Oryon Developer of autologous neuron replacement medicines for neurodegenerative disorders 50Talent top 28%Funding top 45%Innovation top 49%Patents top 49% All 5 signals ▾Talenttop 28% Fundingtop 45% Innovationtop 49% Patentstop 49% Globalbottom 42% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $21.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $21M | 2 mo ago | — | Ole Isacson Co-Founder | — | 20 patents Electroluminescent lighting and flexible EL display technologies with nano‑engineered phosphor layers | — |
| 31 | Aphios Developer of therapeutic products and enabling technology platforms for healthcare | $17M | 20 mo ago | 12 | — | — | 81 patents Pathogen inactivation in blood products and nanotech drug delivery for cannabinoids | — |
| 32 | Holobiome Developer of microbiome-based therapeutics for nervous system disorders | $16M | 20 mo ago | 12 | — | — | 29 patents Therapeutic modulation of gut microbiome for CNS and mental health disorders. | — |
| 33 | Violet Therapeutics Developer of small molecule therapeutics targeting neurodegenerative diseases of the CNS 48Talent top 38%Funding top 39%Global bottom 48% All 3 signals ▾Talenttop 38% Fundingtop 39% Globalbottom 48% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $15.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $15M | 1 mo ago | — | Francisco Quintana Co-Founder | — | — | — |
| 34 | Aquinnah Pharmaceuticals Developer of therapeutics to modulate neurodegenerative stress granules | $15M | 15 mo ago | 4 | — | — | — | — |
| 35 | Micro Leads Precision neuromodulation therapies using minimally-invasive, high-resolution devices for nervous system… | $15M | 14 mo ago | 12 | — | — | — | — |
| 36 | Morphoceuticals Developer of reprogramming software to regenerate tissues and organs | $13M | 20 mo ago | 2 | David Kaplan Co-Founder | Squarespace CommerceSquarespaceTypeScript+18 | 2 patents Computational simulation of electrophysiological responses for biomedical device modeling | — |
| 37 | EnClear Therapies Precision dosing for CNS diseases through innovative neurotechnology platform | $13M | 11 mo ago | 12 | — | — | 79 patents CSF-based drug delivery, monitoring, and pressure control for neuro‑oncology therapies | — |
| 38 | Modulight Biotherapeutics Developer of an optogenetic platform targeting pathological neural activity to restore balance | $12M | 7 mo ago | — | Ofer Yizhar Co-Founder & CSO | — | — | 1 award |
| 39 | NeuroBionics Developer of bioelectronic fibers for neuromodulation and neural interface applications | $10M | 6 mo ago | — | Marc-Joseph Antonini Co-Founder & CEO | WordPressMySQLPHP+21 | 2 patents Implantable neural fiber interfaces for bioelectronic signal recording and stimulation | 3 job openings |
| 40 | Boston Immune Technologies & Therapeutics Developer of immune-based therapies for treating cancer and infectious diseases | $10M | 16 mo ago | 6 | — | — | — | — |
| 41 | Cure Rare Disease Developer of therapeutics to treat rare neuromuscular diseases | $8M | 16 mo ago | 21 | Rich Horgan Founder & CEO | Webflow EcommerceWebflowVimeo+17 | — | — |
| 42 | Rebion Provider vision scanning devices to diagnose brain diseases | $7M | 14 mo ago | 13 | — | Squarespace CommerceSquarespaceStimulus+11 | — | — |
| 43 | Remedium Bio Developer of gene therapies for a broad range of diseases 7Funding top 37%Moat top 48%Global bottom 36%Tech bottom 22% All 5 signals ▾Fundingtop 37% Moattop 48% Globalbottom 36% Techbottom 22% Marketbottom 20% Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 7/100 | $6M | 1 mo ago | 5 | — | Google MapsBootstrapNginx+6 | — | 1 job opening |
| 44 | BrainCo Provider of a prosthetic hand and EEG headband for brain signal 35Funding top 40%Growth top 43%Moat bottom 49%Talent bottom 49% All 9 signals ▾Fundingtop 40% Growthtop 43% Moatbottom 49% Talentbottom 49% Patentsbottom 48% Techbottom 46% Globalbottom 42% Innovationbottom 40% Marketbottom 36% Funding: Raised $5.5M across 2 rounds · 2 rounds over 10 yrs (0.2/yr) Growth: Headcount 43 → 40 (-7%) across vintages · Web rank 50,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 35/100 | $6M | 5 mo ago | 40 | Bicheng Han Founder & CEO | SalesforceAnimate.cssVue.js+9 | 10 patents Neurofeedback-driven brain‑computer interfaces for personalized learning and robotic control | — |
| 45 | Young BioPharma Developer of therapeutics for pain | $4M | 13 mo ago | — | Young Shen Founder | — | — | — |
| 46 | NeuroFieldz AI-powered mobile eye and brain diagnostics for neuro-visual disorders | $3M | 9 mo ago | 3 | Srinivas Sridhar founder | — | — | — |
| 47 | Cerevel Therapeutics 🦄 Developer of therapeutics for neurological and neuropsychiatric disorders | $3M | 12 mo ago | 199 | Tony Coles CEO | — | — | — |
| 48 | BioXyTran Developing platform technologies in Glycovirology, Hypoxia, and Degenerative Diseases | $2M | 3 mo ago | 3 | — | Webflowcore-jsjQuery+10 | 2 patents Patents concentrated in health & consumer products | — |
| 49 | NeuroDex Manufacturer of diagnostic tools for Alzheimer's disease | $1M | 16 mo ago | 13 | Erez Eitan Co-Founder | WordPress Block EditorElementorWordPress+23 | 13 patents Exosome-based biomarkers for diagnosing and monitoring neurodegenerative diseases | 2 launchs · 1 partnership |
| 50 | Sea Pharmaceuticals Developer of therapeutics for the treatment of CNS disorders | $1M | 11 mo ago | 8 | Eduardo Martinez Co-Founder | — | — | — |
Top 12 Neurology companies in Massachusetts
#1
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees$207.8Mraised▾
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees
Developer of small molecule-based therapeutics for the treatment of obstructive sleep apnea. The company has developed a combination of Atomoxetine and Oxybutynin which reduces the obstructive sleep apnea severity. It targets the neurological control and activation of upper airway dilator muscles which improve respiration and oxygenation during sleep.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 14%Growth
top 28%Talent
top 28%Moat
top 35%Product
top 40%Tech
bottom 49%Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Conventional Debt (Apr 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Talent: Analyst team rating 5/5 · 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 22k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Regional Director, Field Medical Affairs
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Conventional Debt$50M
- Mar 2026Series C$25M
- Sep 2025Conventional Debt$35M
- Apr 2025Series C$16.5M
Founders & team
Investors
Tao Capital Partners, Morningside, Alpha Wave Global, Sectoral, Columbia-Seligman Investments, NexPoint
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsDocusign
#2
Series C · Cambridge, Massachusetts · founded 2016 · 42 employees$227Mraised▾
Series C · Cambridge, Massachusetts · founded 2016 · 42 employees
Developer of a medical device for the treatment of Alzheimer's disease. The device uses gamma stimulation which helps in reactivating the immune system of the brain. It results in the reduction of amyloid plaques and tau tangles which are typical hallmarks of the disease.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Talent
top 22%Funding
top 23%Growth
top 35%Moat
top 42%Tech
top 50%Market
bottom 43%Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series C (Mar 2026)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 15k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. Ochsner Health) announced in 12 mo
Funding rounds
- Mar 2026Series C$105M
- Mar 2025Series C$196.3M
- Jun 2024Series B$10.2M
- Jun 2022Series B$108.8M
Founders & team
Investors
Morningside, FoundersX Ventures, Alzheimer's Drug Discovery, LIfT Biosciences, IAG Capital Partners, WS Investment Company
Tech stack
CdnjsCloudflareCraft CmsFacebook PixelGoogle AnalyticsGoogle Tag Manager
#3
Public · Cambridge, Massachusetts · founded 2014 · 101 employees$92.5Mraised▾
Public · Cambridge, Massachusetts · founded 2014 · 101 employees
Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 20%Funding
top 24%Innovation
top 31%Tech
top 33%Moat
top 38%News
top 48%Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 · Latest publication 2026
Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Innovation: 60 patents (top 27% of patent-holders) · 43 filings since 2022 vs 17 in 2017-21
Funding rounds
- Mar 2026Post IPO$240M
- Jan 2024Post IPO$108.9M
- Dec 2020Post IPO$90M
- Oct 2020Post IPO$40M
Investors
RA Capital Management, RTW Investments, Foresite Capital, Perceptive Advisors, Janus Henderson Investors, Biogen
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#4
Acquired · Waltham, Massachusetts · founded 2007 · 10 employees$247Mraised▾
Acquired · Waltham, Massachusetts · founded 2007 · 10 employees
Innovating central nervous system disorder treatments with clinical expertise and patient focus. This biopharmaceutical company is dedicated to developing innovative therapies for central nervous system disorders. Their core expertise lies in clinical development, focusing on designing trials with endpoints directly related to patient benefit. They are committed to recruiting patients who will benefit most from their product candidates. The company's pipeline includes programs targeting schizophrenia and Parkinson's disease. They leverage their skills in clinical development to address unmet needs in these disease areas. They are focused on advancing research and development to improve the lives of individuals affected by these conditions. The company is committed to innovation and scientific rigor in their pursuit of new treatments.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 22%Funding
top 26%Innovation
top 27%Fin. health
bottom 48%Moat
bottom 48%Global
bottom 44%Patents: 216 patents matched (strict assignee match) · 111 filings since 2022 vs 89 in 2017-21 · Latest publication 2025
Funding: Raised $247M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) · Last round Post IPO (Oct 2025)
Innovation: 216 patents (top 12% of patent-holders) · 111 filings since 2022 vs 89 in 2017-21
Funding rounds
- Oct 2025Post IPO$200M
- Jun 2023Post IPO—
- Mar 2016Post IPO$1M
- Mar 2015Post IPO$31M
Investors
Oxford Finance, SVB, Boehringer Ingelheim, Federated Hermes, Vivo Capital, Janus Henderson Investors
Tech stack
BootstrapFont AwesomeGoogle AnalyticsHstsJqueryJquery Migrate
#5
Acquired · Cambridge, Massachusetts · founded 2013 · 48 employees$28.9Mraised▾
Acquired · Cambridge, Massachusetts · founded 2013 · 48 employees
Developer of transformational medicines for neurological disorders. The company combines advanced human cellular models, unique measurement engineering, artificial intelligence, and machine learning into a proprietary platform to discover new drugs for neurological disease. The company's lead candidate is UBE3A for Seizure and Neurodevelopment Disorders.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Talent
top 28%Funding
top 31%AI
top 35%Market
top 50%Global
bottom 29%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $28.9M across 16 rounds · 16 rounds over 8 yrs (2.0/yr) · Last round Series B (Apr 2026)
AI: Product described with: artificial intelligence, machine learning
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Apr 2026Series B—
- Dec 2025Grant (prize money)$3M
- Jul 2025Grant (prize money)$2.1M
- Mar 2025Grant (prize money)$2.2M
Founders & team
Investors
NIH, HHS
#6
Seed · Cambridge, Massachusetts · founded 2021$15.3Mraised▾
Seed · Cambridge, Massachusetts · founded 2021
Developer of small molecule therapeutics targeting neurodegenerative diseases of the CNS. It utilizes a platform to identify cell-to-cell interactions. The lead program is a small molecule inhibitor of EphB3. EphB3 is a receptor tyrosine kinase mediating microglia-astrocyte interactions. These interactions drive glial dysfunction.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Talent
top 38%Funding
top 39%Global
bottom 48%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $15.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Seed (May 2026)
Global: Investors from 1 country beyond United States
Audience (LinkedIn): 874 LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Seed$4.8M
- May 2023Seed$10.6M
Founders & team
Investors
SV Health Investors, UTEC, Partners HealthCare, Ono Venture Investment, LifeSpan Vision Ventures, Mass General Brigham
#7
Series B · Cambridge, Massachusetts · founded 2016 · 38 employees$143.5Mraised▾
Series B · Cambridge, Massachusetts · founded 2016 · 38 employees
QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.2/7.3 channel & CSF cartridge device to remove DPR proteins.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 20%Patents
top 23%Innovation
top 25%Growth
top 26%Moat
top 32%Talent
top 41%Funding: Raised $144M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series B (Aug 2025)
Patents: 69 patents matched (strict assignee match) · 62 filings since 2022 vs 7 in 2017-21 · Latest publication 2026
Innovation: 69 patents (top 25% of patent-holders) · 62 filings since 2022 vs 7 in 2017-21
Audience (LinkedIn): 13k LinkedIn followers
Funding rounds
- Aug 2025Series B$20M
- Mar 2023Series B$88M
- Sep 2022Grant (prize money)$300K
- Jul 2020Grant (prize money)$107.4K
Founders & team
Investors
Polaris Partners, Mission BioCapital, MP Healthcare Venture Management, Dolby Family Ventures, SV Health Investors, Droia Ventures
Tech stack
AccessibeApple Icloud MailCloudflareCloudflare Bot ManagementCookieyesGenesis Blocks
#8
Series B · Cambridge, Massachusetts · founded 2020 · 6 employees$34Mraised▾
Series B · Cambridge, Massachusetts · founded 2020 · 6 employees
Developer of small molecule therapeutics for neurodegenerative disease. The company offers autophagosome-tethering compounds that enhances the degradation of disease-causing protein and non-protein targets.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 27%Talent
top 28%Moat
top 39%News
top 46%Patents
bottom 41%Global
bottom 37%Funding: Raised $34.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Series B (Jan 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · IP moat: 10 patents · Soonicorn
Funding rounds
- Jan 2026Series B$38M
- May 2025Series B$39M
- Jul 2021Series A$30M
- 2020Seed$4M
Founders & team
Investors
Nest Bio Ventures, Matrix Partners China, Sherpa Healthcare Partners, Huagai Capital, MSA Capital, MRLV
#9
Series A · Belmont, Massachusetts · founded 2020$21Mraised▾
Series A · Belmont, Massachusetts · founded 2020
Developer of autologous neuron replacement medicines for neurodegenerative disorders. The company focuses on developing medicines to replace lost neurons. It aims to restore function for Parkinson’s disease and other neurodegenerative disorders.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Talent
top 28%Funding
top 45%Innovation
top 49%Patents
top 49%Global
bottom 42%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $21.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Mar 2026)
Innovation: 20 patents (top 51% of patent-holders)
Funding rounds
- Mar 2026Grant (prize money)—
- Mar 2026Series A$21M
Founders & team
Investors
Byers Capital, Neuro VC
#10
Series C · Wakefield, Massachusetts · founded 2021 · 12 employees$44.1Mraised▾
Series C · Wakefield, Massachusetts · founded 2021 · 12 employees
Developer of gene therapies for the treatment of neurological diseases. The company's lead program is a novel investigational gene therapy treatment for Canavan disease. It is developing a vector, called rAAV-Olig001-ASPA to deliver a therapeutic ASPA gene directly to the oligodendrocyte cells that are responsible for producing myelin to restore the ability of oligodendrocytes to make the ASPA enzyme on their own.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 31%Growth
top 35%Moat
top 45%Patents
top 49%Talent
bottom 49%Innovation
bottom 47%Funding: Raised $44.1M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series C (Dec 2025)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Dec 2025Series C$30.5M
- Mar 2025Conventional Debt$7.5M
- May 2024Conventional Debt$6M
Founders & team
Investors
Panacea Venture
Tech stack
AddtoanyAddtoany Share ButtonsAnimate.CssBootstrapCdnjsCloudflare
#11
Series A · Needham, Massachusetts · founded 2020 · 5 employees$5.6Mraised▾
Series A · Needham, Massachusetts · founded 2020 · 5 employees
Developer of gene therapies for a broad range of diseases. The company is developing a pipeline of a broad range of therapies for immune and age-related conditions which includes RMD 1101 for rheumatology, RMD 1202 for endocrinology, RMD 1501 for neurology, and RMD 1201 for Type-1 diabetes.
Fliar Intelligence Index™ 7how this company ranks against its industry peers
Funding
top 37%Moat
top 48%Global
bottom 36%Tech
bottom 22%Market
bottom 20%Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Global: Investors from 2 countries beyond United States
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 7 hiring posts in 12 mo (public) · momentum -2 · hiring: Research Associate, Scientist/Senior Scientist, Molecular Biology
Activity (LinkedIn): 1 partnerships (incl. Lilly) announced in 12 mo
Funding rounds
- May 2026Series A$1.5M
- Sep 2024Seed—
- Aug 2023Grant (prize money)$275K
- Aug 2022Seed$2.3M
Investors
LifeSpan Vision Ventures, Sherwood Ventures, Longevitytech.fund, Primo Medical Group, Angel Star Ventures, APIS Health Angels
#12
Public · Boston, Massachusetts · founded 2001 · 13 employees$208.9Mraised▾
Public · Boston, Massachusetts · founded 2001 · 13 employees
Developer of therapeutics for neurodegenerative diseases. It offers a lead product neflamapimod an oral, selective small molecule inhibitor of the protein kinase p38 alpha for treating dementia with Lewy bodies and Alzheimer’s disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Mar 2025Grant (prize money)$21.1M
- Mar 2025Grant (prize money)$21.1M
- Mar 2024Post IPO$149.4M
- Feb 2023Grant (prize money)$15M
Founders & team
Investors
HHS, RA Capital Management, Armistice Capital, Soleus Capital, Special Situations Funds
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
Funding & investor landscape
$9.3Btotal disclosed funding
154companies funded
530disclosed rounds
5rounds last 90 days
Most active investors
Atlas Venture11 rounds
Notable founders
Andrew Wellman
Co-Founder · Apnimed
Lawrence Miller
Co-Founder · Apnimed
Ed Boyden
Co-Founder · Cognito Therapeutics
Li-Huei Tsai
Co-Founder · Cognito Therapeutics
Paul Roma
Co-Founder · Quiver Bioscience
Graham Dempsey
Co-Founder · Quiver Bioscience
Meredith Fisher
Co-Founding & CEO · Violet Therapeutics
Francisco Quintana
Co-Founder · Violet Therapeutics
Kasper Roet
Founder & CEO · QurAlis
Huaixiang Hao
Co-Founder · PAQ
Boxun Lu
Co-Founder · PAQ
Ole Isacson
Co-Founder · Oryon
Prism market signals · United States · country-scoped Prism corpus, 672,586 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
RESEARCH IN MASSACHUSETTS · Health & Bio
How research on Neurotech in Massachusetts is moving
A read on the academic research around Neurotech in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 344 papers.
MIT and Massachusetts General Hospital lead Boston's predominantly optimistic neurotech research, focusing on neurological disorder treatments and brain-computer interfaces, with advancements outpacing concerns nearly 3-to-1.
344 papers · stance +0.44 · 26% breakthrough · 18% concern
top institutions
- Massachusetts General Hospital251
- Massachusetts Institute of Technology71
- University of Massachusetts Chan Medical School21
- Massachusetts Eye and Ear Infirmary11
- University of Massachusetts Amherst6
leading researchers
Emad N. Eskandar · Alik S. Widge · Darin D. Dougherty · Witold Lipski · Alan Bush · Angelique C. Paulk
prism intelligence · tone & topics
95% positive · 2% critical tone
HealthMedical ResearchNeuroscienceHealthcareMental HealthMedicine
▲
Breakthroughs78 · 23%
▲ 15%→26% share
▲1.7× share momentum7 median citations58% since 2021mostly methods-led
Deep brain stimulation breakthroughs are surging — papers jumped from 5 to 23, with decoding methods newly emerging at 7.
rising sub-themes (early→recent)
- Deep brain stimulation5→23
- Neuromodulation2→18
- Neuroscience9→21
- Brain–computer interface3→6
- Transcranial magnetic stimulation1→4
Newly emergingDecoding methods 0→7 · Neurostimulation 0→4 · Electrode 0→3
Landmark A high-performance speech neuroprosthesis · 477 cites
◆
Advancements169 · 49%
▼ 55%→45% share
▼0.8× share momentum12 median citations46% since 2021mostly empirical
Basal ganglia advancement research is intensifying — papers rose eightfold from 1 to 8, alongside brain–computer interface quadrupling.
rising sub-themes (early→recent)
- Neurostimulation4→14
- Neuroscience22→30
- Neuromodulation5→12
- Basal ganglia1→8
- Brain–computer interface2→9
Newly emergingGait 0→3 · Encoding (memory) 0→3 · Electroencephalography 0→3
Landmark Two‐year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostim · 632 cites
▼
Concerns56 · 16%
▼ 19%→17% share
▼0.9× share momentum20 median citations54% since 2021mostly empirical
Neuromodulation safety concerns are rising sharply — papers grew from 1 to 7, with mood risks newly flagged.
rising sub-themes (early→recent)
- Neuroscience3→13
- Neuromodulation1→7
- Stimulation2→6
- Deep brain stimulation18→20
- Brain stimulation2→3
Newly emergingMood 0→3
Landmark Closing the Loop on Deep Brain Stimulation for Treatment-Resistant Depression · 150 cites
Common questions
How many Neurology companies are there in Massachusetts, United States?
Radar tracks 212 indexable Neurology companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in Massachusetts, United States?
The Neurology companies in Massachusetts, United States on this list have raised a combined $9.3B in disclosed equity funding across 154 funded companies.
Which is the highest-funded Neurology company in Massachusetts, United States?
Neumora is the highest-funded Neurology company in Massachusetts, United States, with $612M in disclosed equity funding.
How many Neurology companies in Massachusetts, United States are funded?
154 of the 212 Neurology companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in Massachusetts, United States?
1 Neurology company in Massachusetts, United States on this list is valued at $1B or more.
Who are the top investors in Massachusetts, United States Neurology companies?
The most active investors in Massachusetts, United States Neurology companies on this list include HHS, Atlas Venture, NIH, Alexandria, MassChallenge.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.